| __timestamp | Iovance Biotherapeutics, Inc. | Opthea Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 9335772 | 2652041 |
| Thursday, January 1, 2015 | 12390000 | 2361587 |
| Friday, January 1, 2016 | 25602000 | 4472869 |
| Sunday, January 1, 2017 | 21262000 | 5030957 |
| Monday, January 1, 2018 | 28430000 | 4988941 |
| Tuesday, January 1, 2019 | 40849000 | 5196412 |
| Wednesday, January 1, 2020 | 60210000 | 6652774 |
| Friday, January 1, 2021 | 83664000 | 18418247 |
| Saturday, January 1, 2022 | 104097000 | 24827066 |
| Sunday, January 1, 2023 | 106916000 | 41896408 |
| Monday, January 1, 2024 | 15488619 |
Data in motion
In the dynamic world of biotechnology, understanding financial trends is crucial for investors and stakeholders. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent biotech companies: Opthea Limited and Iovance Biotherapeutics, Inc., from 2014 to 2023.
Iovance Biotherapeutics, Inc. has shown a significant upward trend in SG&A expenses, increasing by over 1,000% from 2014 to 2023. This reflects their aggressive expansion and investment in administrative capabilities. In contrast, Opthea Limited's SG&A expenses have grown by approximately 1,500% during the same period, indicating a robust scaling strategy.
The year 2023 marked a peak for both companies, with Iovance's expenses reaching their highest at over $106 million, while Opthea's expenses surged to nearly $42 million. Notably, 2024 data for Iovance is missing, suggesting a potential shift or strategic change.
Breaking Down SG&A Expenses: Teva Pharmaceutical Industries Limited vs Iovance Biotherapeutics, Inc.
Neurocrine Biosciences, Inc. and Iovance Biotherapeutics, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Opthea Limited Trends and Insights
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
Cost Management Insights: SG&A Expenses for Lantheus Holdings, Inc. and Opthea Limited
Opthea Limited or Xenon Pharmaceuticals Inc.: Who Manages SG&A Costs Better?
Opthea Limited and Merus N.V.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Opthea Limited vs MorphoSys AG Trends and Insights
Cost Management Insights: SG&A Expenses for Opthea Limited and Ligand Pharmaceuticals Incorporated
Selling, General, and Administrative Costs: Opthea Limited vs Geron Corporation
Who Optimizes SG&A Costs Better? Arrowhead Pharmaceuticals, Inc. or Iovance Biotherapeutics, Inc.
Mesoblast Limited or Iovance Biotherapeutics, Inc.: Who Manages SG&A Costs Better?